Opinion
Video
Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.
EP: 1.Overview of Molecular Testing and Barriers in mCRC
EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC
Now Viewing
EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
EP: 4.Exploring Toxicities for Second Line Treatments in mCRC
EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
EP: 6.Factors Driving 3L Therapeutic Selection for mCRC
EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial
EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC
EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR
EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer
- Dr Cohen:ZL-IRIAN study (NCT05229003; Wang C, et al. ASCO 2024. Abstract 3570)– Irinotecan plus anlotinib ± penpulimab in 2L mCRC
- Dr Ciombor: Ph II study (Zhao W, et al. ASCO 2024. Abstract 3571) – fruquintinib plus investigator choice of chemotherapy in 2L mCRC
Related Videos
Related Content
